MiNK Therapeutics
Tracked across 11 events · 237 articles · First seen Oct 06, 2025 · Last active Jun 25, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: MiNK Therapeutics is the defendant in a securities fraud class action lawsuit, accused of making materially false and misleading statements regarding its DCCR clinical trial program, which led to a significant stock price decline.
Apr 01, 2026 · 6 articles
Business
Impact: MiNK Therapeutics is being acquired by Neurocrine Biosciences for $2.9 billion, representing a significant premium for its shareholders. Its product, VYKAT XR, is a key asset in this transaction.
Apr 06, 2026 · 6 articles
Tech
Impact: MiNK Therapeutics, a subsidiary of NRx Pharmaceuticals, has transitioned from system deployment to active patient care using the Zeta TMS Navigation System, offering advanced psychiatric and neurological care.
Jun 25, 2026 · 6 articles
Tech
Impact: MiNK Therapeutics, a subsidiary of Bayer, is exploring approaches related to regulatory T cells, contributing to the development of new treatments.
Oct 06, 2025 · 6 articles
100
MiNK Therapeutics treated first patientsHOPE Therapeutics deploys Zeta TMS
80
MiNK Therapeutics installed systems Zeta SurgicalHOPE Therapeutics deploys Zeta TMS
ERGEN INTELLIGENCE
Track MiNK Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard